Epidemiology and Predictors of Mortality in Cases of Candida Bloodstream Infection: Results from Population-Based Surveillance, Barcelona, Spain, from 2002 to 2003
暂无分享,去创建一个
S. Fridkin | Benjamin J Park | M. Cuenca‐Estrella | M. Giménez | J. Rodríguez-Tudela | D. Warnock | B. Almirante | A. Pahissa | J. Mensa | M. Almela | A. Planes | J. Morgan | D. Rodríguez | F. Sánchez | J. Ayats | P. Saballs | D. Rodríguez | Dolors Rodríguez
[1] Patrick R. Murray,et al. Candida, Cryptococcus, and other yeasts of medical importance. , 2006 .
[2] J. A. J. W. Kluytmans,et al. Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals , 2005, European Journal of Clinical Microbiology and Infectious Diseases.
[3] M. Pfaller,et al. Geographic Variation in the Susceptibilities of Invasive Isolates of Candida glabrata to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002 , 2004, Journal of Clinical Microbiology.
[4] Lee H. Harrison,et al. Incidence of Bloodstream Infections Due to Candida Species and In Vitro Susceptibilities of Isolates Collected from 1998 to 2000 in a Population-Based Active Surveillance Program , 2004, Journal of Clinical Microbiology.
[5] D. Pittet,et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] J. Sobel,et al. Guidelines for treatment of candidiasis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] M. Pfaller,et al. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[8] D. Pittet,et al. Management of candidiasis Management of Candida species infections in critically ill patients , 2003 .
[9] E. Baron,et al. Comparison of the Susceptibilities of Candida spp. to Fluconazole and Voriconazole in a 4-Year Global Evaluation Using Disk Diffusion , 2003, Journal of Clinical Microbiology.
[10] A. Tortorano,et al. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood. , 2003, The Journal of antimicrobial chemotherapy.
[11] D. Denning,et al. Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts , 2003 .
[12] V. Anttila,et al. Candidemia in Finland, 1995–1999 , 2003, Emerging infectious diseases.
[13] W. Gransden,et al. Management and outcome of bloodstream infections due to Candida species in England and Wales. , 2003, The Journal of hospital infection.
[14] J. L. López Sastre,et al. Neonatal Invasive Candidiasis: A Prospective Multicenter Study of 118 Cases , 2003, American journal of perinatology.
[15] M. Fariñas,et al. Candidemia in a Tertiary Care Hospital: Epidemiology and Factors Influencing Mortality , 2003, European Journal of Clinical Microbiology and Infectious Diseases.
[16] J. L. López Sastre,et al. Neonatal invasive candidiasis: a prospective multicenter study of 118 cases. , 2003, American journal of perinatology.
[17] D. Pittet,et al. Management of Candida species infections in critically ill patients. , 2003, The Lancet. Infectious diseases.
[18] D. Pittet,et al. Secular Trends of Candidemia Over 12 Years in Adult Patients at a Tertiary Care Hospital , 2002, Medicine.
[19] J. Pemán,et al. Candidemia at a Tertiary-Care Hospital: Epidemiology, Treatment, Clinical Outcome and Risk Factors for Death , 2002, European Journal of Clinical Microbiology and Infectious Diseases.
[20] M. Pfaller,et al. Role of Sentinel Surveillance of Candidemia: Trends in Species Distribution and Antifungal Susceptibility , 2002, Journal of Clinical Microbiology.
[21] L. R. Ásmundsdóttir,et al. Increasing Incidence of Candidemia: Results from a 20-Year Nationwide Study in Iceland , 2002, Journal of Clinical Microbiology.
[22] R. Gaynes,et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] A. Tortorano,et al. European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. , 2002, The Journal of hospital infection.
[24] H. Richet,et al. Candidemia in French hospitals: incidence rates and characteristics. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[25] M. Pfaller,et al. Epidemiology of Candidemia: 3-Year Results from the Emerging Infections and the Epidemiology of Iowa Organisms Study , 2002, Journal of Clinical Microbiology.
[26] J. Pemán,et al. [Epidemiology of candidemia in Spain - Multicenter study] , 2002, Revista iberoamericana de micologia.
[27] D. Sanglard,et al. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. , 2002, The Lancet. Infectious diseases.
[28] E. Anaissie,et al. Revisiting the source of candidemia: skin or gut? , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] M. Pfaller,et al. International Surveillance of Bloodstream Infections Due toCandida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program , 2001, Journal of Clinical Microbiology.
[30] L. Mermel,et al. Guidelines for the Management of Intravascular Catheter-Related Infections , 2001, Infection Control & Hospital Epidemiology.
[31] Albert Balows,et al. Manual of Clinical Microbiology, 7th ed. , 2000 .
[32] T. C. White,et al. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. , 2000, The Journal of infectious diseases.
[33] R. Pinner,et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[34] M Mazumdar,et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] D. McClish,et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[36] B. Lebeau,et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[37] R. Cisterna,et al. [Description of 165 episodes of fungemia: A multicenter study.]. , 1999, Revista iberoamericana de micologia.
[38] M. Steinbakk,et al. Constant Low Rate of Fungemia in Norway, 1991 to 1996 , 1998, Journal of Clinical Microbiology.
[39] E. Kossoff,et al. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. , 1998, The Pediatric infectious disease journal.
[40] Ronald N. Jones,et al. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. , 1998, Diagnostic microbiology and infectious disease.
[41] M. White. The contribution of fluconazole to the changing epidemiology of invasive candidal infections. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[42] E. Anaissie,et al. The epidemiology of hematogenous candidiasis caused by different Candida species. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[43] A. Sitges-Serra,et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy , 1997, Intensive Care Medicine.
[44] D. Snydman,et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. , 1996, The American journal of medicine.
[45] J. Wingard,et al. Importance of Candida species other than C. albicans as pathogens in oncology patients. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[46] M. Larocco,et al. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period , 1994, Antimicrobial Agents and Chemotherapy.
[47] C. Beck-Sague,et al. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. , 1993, The Journal of infectious diseases.
[48] W J Martone,et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. , 1991, The American journal of medicine.
[49] R. Chang,et al. Predicting outcome among intensive care unit patients using computerised trend analysis of daily Apache II scores corrected for organ system failure , 1988, Intensive Care Medicine.
[50] E. Bruck,et al. National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.